Beijing, China – August 15, 2018 –Tianjin Novogene Bioinformatics Technology Company LTD, a fully-owned subsidiary of Novogene Co., received CFDA approval for its NovoFocus NSCLC CDx Test today. This is a next-generation sequencing (NGS)-based diagnostic test that simultaneously analyzes tumor samples for multiple genomic mutations associated with several CFDA-approved targeted therapies for non-small cell lung cancer (NSCLC), which accounts for ~80% of all lung cancers in China.
The NovoFocus NSCLC CDx Test was developed on the Thermo Fisher Ion Proton™ sequencing platform (approved by CFDA as “DA8600” in January 2017 for the diagnosis of cancer and inherited diseases). The reagent kits for sample processing and library construction, as well as the data analysis and result reporting software system, were developed by Novogene. Following this CFDA approval, results from the sequencing and analysis of three genes, EGFR, ALK and ROS1, can be used to identify NSCLC patients who may be eligible for treatment by CFDA-approved targeted therapies Gefitinib (IRESSA®), Osimertinib (TAGRISSO®) and Crizotinib (XALKORI®), respectively. Results on the other three genes, KRAS, BRAF and PIK3CA, can be considered by clinicians together with other test results and the patient’s disease characteristics during clinical decision making.
Figure: CFDA announcement for the approval of the NovoFocus NSCLC CDx Test
Ion Proton™ is a registered trademark of Thermo Fisher; IRESSA® and TAGRISSO® are registered trademarks of AstraZeneca; and XALKORI® is a registered trademark of Pfizer.
Novogene is a leading provider of genomic services and solutions with cutting-edge NGS and bioinformatics expertise and the largest sequencing capacity in the world. Novogene utilizes scientific excellence, a commitment to customer service and unsurpassed data quality to help our clients realize their research goals in the rapidly evolving world of genomics. Novogene delivers unsurpassed data quality to support our customers’ research goals. We are a world-leader in NGS services, with thousands of employees and multiple locations across the globe. Novogene delivers unsurpassed data quality to support our customers’ research goals. We are a world-leader in NGS services, with thousands of employees and multiple locations across the globe. Novogene has strong scientific expertise and experience with 32 NGS-related patents, as well as over 580 research papers with total impact factor at more than 4090, including publications in first tiers journals such as Cell, Nature and Science. For more information, visit novogene.com/us-en.
The field is required.